



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

Equality impact assessment

Medicine name: Trifarotene (Akliel[®]▼)

Submission reference number: 3153

Indication: For the cutaneous treatment of *Acne Vulgaris* of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present

New Medicines Group meeting date: 28 February 2024

All Wales Medicines Strategy Group (AWMSG) meeting date: 17 April 2024

The impact of this medicine on equality has been assessed during this appraisal.

Have any potential equality issues been identified for this medicine? If so, what are they?

The Medicines and Healthcare products Regulatory Agency (MHRA) advises that systemic exposure is thought to be negligible following application of topical retinoids. However, since risk cannot be excluded, use of topical retinoids is contraindicated during pregnancy as a precaution; the MHRA advises females of childbearing potential should use effective contraception. Prescribers should take account of the Summary of Product Characteristics (SmPC) for the medicine indicates that Akliel[®] is contraindicated during pregnancy or in women planning a pregnancy. If the product is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued.

Would the availability of the medicine result in different impacts for protected groups (age, gender, gender reassignment, disability, pregnancy and maternity, marriage or civil partnership, race, religion or belief, sexual orientation)?

Pregnancy and maternity (See above).

Would it be more difficult in practice for a specific group to access the medicine, compared with other groups? If so, what are those barriers or difficulties? Are there any recommendations that AWMSG could make to remove or alleviate difficulties with access?

No. All groups will have access to the medicine via their primary care provider.

How will any equality issues be addressed?

The SmPC criteria specify which people are excluded from treatment due to the associated risks of treatment. This will be identified for consideration of any change to the advice at the next review if there is a change to the current advice for pregnant and breastfeeding women.

Does the medicine relate to an area with known health inequalities?



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

No
Is a full equality and health impact assessment needed?
No
Actions: Patient organisations/patients/members of the public are invited to comment on the submission via the AWTTC website. The SmPC criteria specify which people are excluded from treatment due to the associated risks of treatment. This will be identified for consideration of any change to the advice at the next review if there is a change to the current advice for pregnant and breastfeeding women.

Approved by: Kelly Layton (Senior Appraisal Scientist)

Date: 04/01/2024

Date of next review: 04/01/2027